The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform.
